核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理_陈成伟.pdfVIP

2013 02 28 26 1 传染病信息 年 月 日 第 卷 第 期 Infect Dis Info, Vol. 26, No. 1, February 28, 2013 ·1 · ·特别报道· 核苷和核苷酸类药物 治疗慢性乙型肝炎的耐药及其管理 参加乙型肝炎病毒耐药讨论会专家 [ ] 摘要 中国国家食品药品监督管理局已批准4 类核苷和核苷酸类药物（nucleoside and nucleotide analogs, NAs）用于慢性 乙型肝炎患者（chronic hepatitis B, CHB）治疗。用这些药物可对CHB 患者进行有效治疗，但常发生乙型肝炎病毒（HBV）对NAs 的耐药，导致治疗失败和疾病进展。本文综述了HBV 对NAs 的耐药机制，以及专家对耐药管理和预防的共识。 [ ] 关键词 肝炎，乙型，慢性；耐药；核苷和核苷酸类药物；管理 [ ] [ ] [ ] 中国图书资料分类号 R512.62 文献标志码 A 文章编号 1007-8134(2013)01-0001-09 Drug resistance to nucleoside and nucleotide analogs in chronic hepatitis B and its management Experts Attending the Discussionon Hepatitis B Virus Drug Resistance corresponding author. ZHUANG Hui, Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China, E-mail: zhuangbmu@126.com; WENG Xin-hua, Department of Infectious Disease, Huashan Hospital, Fudan University, Shanghai 200040, China, E-mail: xinhua_weng@ [Abstract] Four nucleos(t)ide analogs (NAs) have been approved by the Food and Drug Administration, China for treatment of patients with chronic hepatitis B (CHB)． The patients can be successfully treated using NAs ， but drugresistant hepatitis B virus (HBV) mutants frequently arise, leading to treatment failure and progression of the disease． This paper has reviewed the mechanisms of resistance to NAs, and consensus on the management and prevention of HBV resistance to NAs． [Key words] hepatitis B, chronic; drug resistance; nucleoside and nucleotide analogs; management 在核苷和核苷酸类药物（nucleoside and nucleo- 志》、《中国预防医学杂志》、《中华肝脏病杂志》、《中 t